2020
Status of racial disparities between black and white women undergoing assisted reproductive technology in the US
Seifer D, Simsek B, Wantman E, Kotlyar A. Status of racial disparities between black and white women undergoing assisted reproductive technology in the US. Reproductive Biology And Endocrinology 2020, 18: 113. PMID: 33213467, PMCID: PMC7677830, DOI: 10.1186/s12958-020-00662-4.Peer-Reviewed Original ResearchConceptsCumulative live birth rateLive birth rateReproductive technology outcomesWhite non-Hispanic womenBody mass indexEtiology of infertilityNon-Hispanic womenMass indexBirth rateBlack womenWhite non-Hispanic patientsTechnology outcomesLogistic regressionWhite womenRetrospective cohort studyNon-Hispanic patientsIndependent prognostic factorIntra-cytoplasmic sperm injectionProportion of cyclesMultivariate logistic regressionMultiple logistic regressionReproductive technologiesNumber of embryosCycle cancellationOvarian reserve
2014
Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011
Butts SF, Owen C, Mainigi M, Senapati S, Seifer DB, Dokras A. Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011. Fertility And Sterility 2014, 102: 1041-1047.e1. PMID: 25086790, PMCID: PMC4184996, DOI: 10.1016/j.fertnstert.2014.06.043.Peer-Reviewed Original ResearchMeSH KeywordsChi-Square DistributionEmbryo Culture TechniquesEmbryo TransferFemaleHumansInfertility, FemaleLive BirthLogistic ModelsOdds RatioOvarian ReservePregnancyPregnancy RatePrimary Ovarian InsufficiencyRegistriesRetrospective StudiesRisk FactorsSperm Injections, IntracytoplasmicTime FactorsTreatment OutcomeUnited StatesConceptsDiminished ovarian reserveIntracytoplasmic sperm injectionElevated FSHLive birthsOvarian reserveART cyclesSperm injectionAssisted Reproductive Technology Clinic Outcome Reporting System databaseClinical pregnancy rateRetrospective cohort studyLive birth rateReproductive technology outcomesAssisted reproduction cyclesCombination of ICSIReporting System databaseCohort studyPrimary diagnosisImproved outcomesPregnancy rateMAIN OUTCOMELower oddsDiminished oddsFSHOnly indicationTechnology outcomes
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction